This resulted in the approval of combined CDK4/6i and an aromatase inhibitor (AI) for ER+ advanced breast cancer as first-line treatment (1, 8, 9) and as second-line therapy in combination with the selective estrogen-receptor degrader (SERD) fulvestrant following initial AI monotherapy (10–12). This evidence concerns the gene ESR1 and breast carcinoma.